Avian transgenesis via site-directed integration

Information

  • Research Project
  • 6736593
  • ApplicationId
    6736593
  • Core Project Number
    R43GM068139
  • Full Project Number
    1R43GM068139-01A1
  • Serial Number
    68139
  • FOA Number
  • Sub Project Id
  • Project Start Date
    1/15/2004 - 21 years ago
  • Project End Date
    6/14/2004 - 20 years ago
  • Program Officer Name
    GRIEDER, FRANZISKA B
  • Budget Start Date
    1/15/2004 - 21 years ago
  • Budget End Date
    6/14/2004 - 20 years ago
  • Fiscal Year
    2004
  • Support Year
    1
  • Suffix
    A1
  • Award Notice Date
    12/18/2003 - 21 years ago

Avian transgenesis via site-directed integration

[unreadable] DESCRIPTION (provided by applicant): [unreadable] [unreadable] This SBIR project describes a novel method to create transgenic poultry that will produce biopharmaceutical proteins in their eggs. Poultry, including chickens and quail, are able to produce large amounts of protein in their eggs at relatively low cost. We seek to harness this capability to synthesize pharmaceutical proteins, such as humanized monoclonal antibodies, that are needed in large amounts. The efficiency of transgenesis in avians, particularly with large transgenes, is exceedingly low. We propose here to overcome this hurdle by the use of integration-promoting enzymes, which are able to recombine specific DNA sequences with a high efficiency. In Phase I of this project we will optimize the activity of integration promoting enzymes so that it is applicable in the early avian embryo. We will also evaluate the integration of large transgenes (i.e. up to 190 kilobasepairs), including bacterial artificial chromosomes. In Phase II of this project, the integration-promoting enzymes will be used to insert transgenes encoding pharmaceutical proteins, and driven by egg white specific promoters, into the genome of poultry. This novel technology will expedite the creation of poultry that can produce pharmaceuticals, thereby facilitating drug development, enhancing clinical trials and lowering the cost of pharmaceuticals. [unreadable] [unreadable]

IC Name
NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES
  • Activity
    R43
  • Administering IC
    GM
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    90000
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    821
  • Ed Inst. Type
  • Funding ICs
    NIGMS:90000\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    SYNAGEVA BIOPHARMA CORPORATION
  • Organization Department
  • Organization DUNS
    967296187
  • Organization City
    Waltham
  • Organization State
    MA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    02451
  • Organization District
    UNITED STATES